Recommendations
3 to acquire · 0 to dispose
| Ticker | Name | Close | Action | Action Price Where to act — a buy-limit on a pullback or a buy-stop above resistance, not the current price. Sanity-check vs Close: on a held name, an action price stranded above the close means the queued level was set when the stock was higher — stale, awaiting reprice. | Stop The risk-defined exit, set below the entry for a long (~1.2–1.8×ATR). A held long whose Stop sits at/above the Close is already below its stop — a stale box awaiting reprice. | 1wk Model estimate of the likely price at this horizon — a forward projection, not a guarantee, and separate from the trade's Action Price or Stop. Where the ML estimator is enabled these are per-ticker calibrated forecasts (~80% coverage band) that are refreshed periodically and can drift between refreshes; otherwise they're interpolated from the signal's swing target. Confirm against the settled close. | 4wk Model estimate of the likely price at this horizon — a forward projection, not a guarantee, and separate from the trade's Action Price or Stop. Where the ML estimator is enabled these are per-ticker calibrated forecasts (~80% coverage band) that are refreshed periodically and can drift between refreshes; otherwise they're interpolated from the signal's swing target. Confirm against the settled close. | 12wk Model estimate of the likely price at this horizon — a forward projection, not a guarantee, and separate from the trade's Action Price or Stop. Where the ML estimator is enabled these are per-ticker calibrated forecasts (~80% coverage band) that are refreshed periodically and can drift between refreshes; otherwise they're interpolated from the signal's swing target. Confirm against the settled close. | Rationale |
|---|---|---|---|---|---|---|---|---|---|
| XLV | Health Care Select Sector SPDR | 172.95 | BUY — QUEUED @171.10 | 171.10 | 168.25 | 173.07 (+1.2%) | 173.22 (+1.2%) | 169.90 (-0.7%) | Healthcare is the market's clearest leadership rotation right now: XLV has gained roughly 16% since semiconductors peaked on 22 June, and it is the highest-conviction print on the entire sector board (STRONG BUY, conviction 85, Buy_Rank 1) on a PullbackBuy_VWAP setup -- this book's most reliable buy family. With the 10-year Treasury at 4.79%, its highest since 2023, and a US-Iran flare-up keeping Brent near defensive healthcare earnings are exactly what the tape is paying for. We are buying the pullback, not the price: a limit at sits 1.07% below Wednesday's close and only fills if the market comes to us. OPERATIONAL: Entry_Distance_ATR -0.76 means price is extended above the model entry, so this is queued rather than taken at market (no-chase rule). Risk is tight -- per share to the stop, 2.0x reward-to-risk against the target. SE-2 CAVEAT: the 12-week estimate is BELOW the entry -- an inverted forward horizon, endemic to bullish ETF prints in this book -- so size and time this as a <=4-week tactical swing with a planned exit, never a position hold. SE-3: 1wk estimate carries a low-reliability flag (calib_1w -0.08, degenerate). scorecard_bias +0 (PullbackBuy_VWAP|buy n=10, hit_1w 0.50, actionable, neutral). Sizing: rank-weighted share of the (85.49/220.22) = / = =. Expires after 3 sessions (2026-09-08) or on conviction <65. · news |
| IBB | iShares Biotech ETF | 213.80 | BUY — QUEUED @207.06 | 207.06 | 201.82 | 213.63 (+3.2%) | 216.16 (+4.4%) | 224.35 (+8.4%) | Biotech is up more than 20% since the June semiconductor peak on a genuinely fundamental story -- a more flexible FDA on serious-disease approvals, heavy M&A, improved financing and AI-driven drug discovery -- rather than multiple expansion, and drug-pricing policy risk is now quantified rather than feared. IBB closed +1.41%, the strongest sector-ETF gain on the board, on a STRONG BUY (conviction 79, Buy_Rank 2) PullbackBuy_VWAP print, and it carries the healthiest forward view of any acquire today: +4.4% at four weeks and +8.4% at twelve, with no inversion. OPERATIONAL: Entry_Distance_ATR -1.49 -- price is deeply extended above the model entry, so this is a patient GTC limit 3.15% below the close and may well never fill; that is the intended discipline, not a defect. Reward-to-risk 2.0x (stop distance vs to the target). scorecard_bias +0 (PullbackBuy_VWAP|buy actionable, neutral). SE-3: 1wk estimate low-reliability. Sizing: 85.49/220.22 of = / = =. Expires 2026-09-08 or on conviction <65. Watch: a hot 09-04 payrolls print pushes long rates higher and long-duration biotech is the first thing sold -- if that happens the limit fills on the wrong kind of weakness, so re-validate at the open. · news |
| XLF | Financial Select Sector SPDR | 57.66 | BUY | 57.93 | 57.14 | 57.57 (-0.6%) | 57.93 (+0.0%) | 57.51 (-0.7%) | Financials are the one place a stubbornly high long end is a tailwind rather than a tax: with the 10-year at 4.79% and New York Fed President Williams saying there are 'no clear signs right now' that a September hike is needed, banks get the steep curve without the recession scare, and XLF closed +0.80% on a PullbackBuy_VWAP BUY (conviction 74, Buy_Rank 3). This is the one acquire we actually execute at the open rather than queue -- the model entry of sits above Wednesday's close, so it is immediately marketable and needs no pullback. OPERATIONAL: this is deliberately the smallest of the three cards and it is taken on the signal, not the forward view -- BE HONEST ABOUT THE EXPECTANCY: the estimator's 1wk (-0.62%), 4wk (0.00%) and 12wk (-0.73%) points are all flat-to-negative versus the action price. Under SE-2 this is a <=4-week tactical swing to the target (+2.74%) against a stop (-1.36%), 2.0x reward-to-risk, with a planned exit -- not a hold. Regime is Transitional and the trail flickered BUY|BUY|WATCH|BUY, so stability is weaker than SKYY's. Chosen over SKYY (adj 73) on the adjusted-conviction rank by a single point; SKYY is the standing near-miss. scorecard_bias +0. Sizing: 49.24/220.22 of = / = =. Key risk: 09-04 payrolls is the direct test -- a soft print revives cut expectations and flattens the curve against this thesis. · news |
| — | First Trust Cloud Computing ETF | — | NO ACTION | — | — | n/a | n/a | n/a | Top near-miss and the most stable signal on the board -- four consecutive BUY prints (69/62/73/73) and the only acquire-grade name with a positive forward view at all three horizons. Declined by one adjusted-conviction point to XLF (73 vs 74). The tie-break also reads as a warning: SKYY was one of only two red names on a 20-green session (-0.88% against a +0.46% S&P), and that relative weakness is the same rate story that vetoed it on 09-01 -- the 10-year at 4.79%, its highest since 2023, hits debt-heavy cloud and AI-infrastructure hardest. Williams framing the yield move as growth-driven rather than inflation-driven is mildly helpful, but two amplifiers sit inside seven sessions (09-04 payrolls, 09-11 CPI). Re-arm trigger: SKYY outperforming QQQ on an up day, or a close back above on conviction >=73. |
| — | SPDR S&P Biotech ETF | — | NO ACTION | — | — | n/a | n/a | n/a | Best raw payoff on the board -- 3.1x reward-to-risk and a +6.9% twelve-week estimate on the same friendly-FDA/M&A biotech story driving IBB -- but declined for the third consecutive session on two grounds. First, adj conviction 67 (69 raw, scorecard_bias -2) ranks it fifth. Second, the recurring structural flaw: the stop is a 0.50-ATR family constant worth only 1.87% on a name whose daily ATR is 2.87%, so ordinary noise stops it out. FailedBreakdown_Up_20D|buy is this book's actionable-negative cell (SE-1: n=14, hit_1w 0.385). IBB is the cleaner expression of the identical thesis. |
| — | Roundhill Magnificent Seven ETF | — | NO ACTION | — | — | n/a | n/a | n/a | Recovered to BUY cv68 after collapsing to NO TRADE cv0 on 09-01, but adj 66 after the -2 FailedBreakdown haircut leaves it sixth. The stop is 0.80% away -- 0.62 ATR -- which is not a survivable risk line. Withdrawn on 08-28 and not re-recommended; not filling has now saved 0.45% versus the original reference. |
| — | Global X AI & Tech ETF | — | NO ACTION | — | — | n/a | n/a | n/a | BUY cv67 -> adj 65, exactly at the floor and seventh in rank, on the book's weakest buy family (SE-1). Closed +0.03%, effectively flat on a 20-green tape -- AI/tech did not participate in the bounce. The stop is 0.73% away, a half-ATR constant. Declined. |
| — | SPDR Dow Jones Industrial Avg | — | NO ACTION | — | — | n/a | n/a | n/a | WATCH cv64 -> adj 62, below the 65 floor. Closed +0.54% with the Dow up 295 points to 53,061.95, but RSI 49.3 and Ranging regime -- a bounce inside a range, not a trend. |
| — | SPDR S&P 500 ETF | — | NO ACTION | — | — | n/a | n/a | n/a | WATCH cv59 -> adj 57. S&P closed +0.46% at 7,666.60, snapping a two-day losing streak as oil pared gains and Williams cooled September hike talk. Below the floor; the index gauge is constructive but not actionable. |
| — | Consumer Staples SPDR | — | NO ACTION | — | — | n/a | n/a | n/a | WATCH cv64 -> adj 62. +0.33%, RSI 50.5, Ranging. Defensives held their bid but staples lagged healthcare badly -- the defensive rotation is going into XLV/IBB, not XLP. |
| — | Technology Select Sector SPDR | — | NO ACTION | — | — | n/a | n/a | n/a | WATCH cv57 -> adj 55, and the conviction trail is decaying 69/62/63/57. Closed -0.02%, one of only two red names on a 20-green board. Tech is not participating in this bounce. |
| — | Invesco QQQ (Nasdaq-100) | — | NO ACTION | — | — | n/a | n/a | n/a | NO TRADE cv0 after WATCH cv52. Nasdaq +0.45% to 26,217.83 but the engine sees nothing: RSI 47.6, no signal. The mega-cap complex is range-bound. |
| — | VanEck Semiconductor ETF | — | NO ACTION | — | — | n/a | n/a | n/a | NO TRADE cv0, +0.96%. RSI 44.6 and still below the EMA ladder. Semis have led nothing since the 22 June peak -- the source of the healthcare rotation this book is now buying. |
| — | iShares Semiconductor ETF | — | NO ACTION | — | — | n/a | n/a | n/a | NO TRADE cv0, +0.23%, RSI 41.4. Same read as SMH; Broadcom's fiscal Q3 after Wednesday's close is the near-term catalyst. |
| — | Industrial Select Sector SPDR | — | NO ACTION | — | — | n/a | n/a | n/a | NO TRADE cv0, +0.03%, RSI 30.6 -- the most oversold name on the board for a second session and it barely bounced on a 20-green tape. That is weakness, not a setup. |
| — | iShares Russell 2000 ETF | — | NO ACTION | — | — | n/a | n/a | n/a | NO TRADE cv0 but +1.18%, a strong bounce off the yield shock. RSI 44.6, no engine signal. Small caps remain the purest read on rate relief. |
| — | SPDR Gold Shares | — | NO ACTION | — | — | n/a | n/a | n/a | NO TRADE cv0, +1.52%, recovering most of the prior session's -2.86%. Gold reasserting itself as the US-Iran situation stayed hot confirms the 09-01 read that the real-rate move, not the war, drove that drop. |
| — | Destiny Tech100 Inc | — | NO ACTION | — | — | n/a | n/a | n/a | WATCH cv42, +3.48% -- the board's biggest gainer, and the only non-ETF row with a valuation read: OVERVALUED_VS_RI, MoS_FV -0.78, val_adj -4 -> adj 38. Well below the floor. Its NAV premium to private marks makes it a sentiment gauge, not a tradeable. |
| — | Consumer Discretionary SPDR | — | NO ACTION | — | — | n/a | n/a | n/a | AVOID cv59 on FailedBreakout_Down_20D. +0.24%, RSI 43.5. Long-only book: no action, and the bearish print argues against any dip-buy here. |
| — | Procure Space ETF (SpaceTech) | — | NO ACTION | — | — | n/a | n/a | n/a | AVOID cv76 on FailedBreakout_Down_20D -- conviction jumped in the bearish direction, the strongest bearish read on the board. +0.91% and RSI 35.2. Long-only: no action, and firmly off the buy list. |
| — | Defiance Quantum ETF | — | NO ACTION | — | — | n/a | n/a | n/a | AVOID cv69 on RallySell_BearTrend, a new bearish print after three sessions of NO TRADE. +0.11%, RSI 42.4. Long-only: no action. |
Outcome & track record
Accuracy at the time of this record.
38 Graded decisions Past recommendations old enough to score against what actually happened (target hit / stopped out / closed). This is the evidence base — the bigger the number, the more history behind the calls. Click to inspect every one. See the decisions →
-0.080 1-week calibration How much of the eventual 4-week move typically shows up in the first week (0 = almost none, 1 = most of it). Use it to read the 1-week estimates: a low number means prices drift toward the target slowly, so don't over-read a soft week-1.
50 Published records How many dated end-of-day verdicts exist for this book — the length of the public track record you can browse in the Archive below.